During the high profile JPMorgan Healthcare Conference, Motley Fool health care bureau chief Brenton Flynn took a moment to look back at some of the interesting things he observed. In this segment of the video, he discusses a prostate-cancer-focused biotech Medivation (MDVN +0.00%) and its presentation -- and three potential share price catalysts.
